Idiopathic Pulmonary Fibrosis – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 17 PAGES: 112

More Info
									    Idiopathic Pulmonary Fibrosis – Pipeline Review, H1
                           2012


                                                                                          Reference Code: GMDHC1756IDB
                                                                                           Publication Date: February 2012




Idiopathic Pulmonary Fibrosis – Pipeline Review, H1 2012                                   GMDHC1756IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Idiopathic Pulmonary Fibrosis – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 6
    List of Figures ................................................................................................................................................................................ 7
Introduction......................................................................................................................................................................................... 8
    Global Markets Direct Report Coverage ........................................................................................................................................ 8
Idiopathic Pulmonary Fibrosis Overview ............................................................................................................................................ 9
Therapeutics Development............................................................................................................................................................... 10
    An Overview of Pipeline Products for Idiopathic Pulmonary Fibrosis .......................................................................................... 10
Idiopathic Pulmonary Fibrosis Therapeutics under Development by Companies ............................................................................. 12
Idiopathic Pulmonary Fibrosis Therapeutics under Investigation by Universities/Institutes .............................................................. 14
Late Stage Products ......................................................................................................................................................................... 15
    Comparative Analysis .................................................................................................................................................................. 15
Mid Clinical Stage Products.............................................................................................................................................................. 16
    Comparative Analysis .................................................................................................................................................................. 16
Early Clinical Stage Products ........................................................................................................................................................... 17
    Comparative Analysis .................................................................................................................................................................. 17
Pre-Clinical Stage Products.............................................................................................................................................................. 18
    Comparative Analysis .................................................................................................................................................................. 18
Idiopathic Pulmonary Fibrosis Therapeutics – Products under Development by Companies ........................................................... 19
Idiopathic Pulmonary Fibrosis Therapeutics – Products under Investigation by Universities/Institutes ............................................ 20
Companies Involved in Idiopathic Pulmonary Fibrosis Therapeutics Development.......................................................................... 21
    Genzyme Corporation ................................................................................................................................................................. 21
    Johnson & Johnson ..................................................................................................................................................................... 22
    Boehringer Ingelheim GmbH ....................................................................................................................................................... 23
    United Therapeutics Corporation ................................................................................................................................................. 24
    Sanofi-Aventis ............................................................................................................................................................................. 25
    Gilead Sciences, Inc. ................................................................................................................................................................... 26
    FibroGen, Inc. .............................................................................................................................................................................. 27
    Novartis AG ................................................................................................................................................................................. 28
    Actelion Ltd .................................................................................................................................................................................. 29
    InterMune, Inc.............................................................................................................................................................................. 30
    Celgene Corporation ................................................................................................................................................................... 31
    Geron Corporation ....................................................................................................................................................................... 32
    Oncothyreon Inc .......................................................................................................................................................................... 33
    Compugen Ltd. ............................................................................................................................................................................ 34
    LTT Bio-Pharma Co., Ltd............................................................................................................................................................. 35
    Promedior, Inc. ............................................................................................................................................................................ 36
    GenKyoTex S.A. .......................................................................................................................................................................... 37
    Amira Pharmaceuticals, Inc. ........................................................................................................................................................ 38
    Stromedix, Inc.............................................................................................................................................................................. 39
    ImmuneRegen BioSciences, Inc.................................................................................................................................................. 40
    ImmuneWorks, LLC ..................................................................................................................................................................... 41



Idiopathic Pulmonary Fibrosis – Pipeline Review, H1 2012                                                                                    GMDHC1756IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Idiopathic Pulmonary Fibrosis – Pipeline Review, H1 2012




    Pacific Therapeutics Ltd. ............................................................................................................................................................. 42
Idiopathic Pulmonary Fibrosis – Therapeutics Assessment ............................................................................................................. 43
    Assessment by Monotherapy Products ....................................................................................................................................... 43
    Assessment by Combination Products ........................................................................................................................................ 44
    Assessment by Route of Administration ...................................................................................................................................... 45
    Assessment by Molecule Type .................................................................................................................................................... 47
Drug Profiles..................................................................................................................................................................................... 50
    Aviptadil - Drug Profile ................................................................................................................................................................. 50
        Product Description................................................................................................................................................................. 50
        Mechanism of Action ............................................................................................................................................................... 50
        R&D Progress ......................................................................................................................................................................... 50
    GC1008 - Drug Profile ................................................................................................................................................................. 51
        Product Description................................................................................................................................................................. 51
        Mechanism of Action ............................................................................................................................................................... 51
        R&D Progress ......................................................................................................................................................................... 51
    JNK CC-930 - Drug Profile .......................................................................................................................................................... 52
        Product Description................................................................................................................................................................. 52
        Mechanism of Action ............................................................................................................................................................... 52
        R&D Progress ......................................................................................................................................................................... 52
    Esbriet - Drug Profile ................................................................................................................................................................... 53
        Product Description................................................................................................................................................................. 53
        Mechanism of Action ............................................................................................................................................................... 53
        R&D Progress ......................................................................................................................................................................... 53
    FG-3019 - Drug Profile ................................................................................................................................................................ 55
        Product Description................................................................................................................................................................. 55
        Mechanism of Action ............................................................................................................................................................... 55
        R&D Progress ......................................................................................................................................................................... 55
    Macitentan - Drug Profile ............................................................................................................................................................. 57
        Product Description................................................................................................................................................................. 57
        Mechanism of Action ............................................................................................................................................................... 57
        R&D Progress ......................................................................................................................................................................... 57
    Homspera - Drug Profile .............................................................................................................................................................. 59
        Product Description................................................................................................................................................................. 59
        Mechanism of Action ............................................................................................................................................................... 59
        R&D Progress ......................................................................................................................................................................... 59
    PC-SOD - Drug Profile ................................................................................................................................................................ 61
        Product Description................................................................................................................................................................. 61
        Mechanism of Action ............................................................................................................................................................... 61
        R&D Progress ......................................................................................................................................................................... 61
    CGEN-25009 - Drug Profile ......................................................................................................................................................... 63
        Product Description................................................................................................................................................................. 63
        Mechanism of Action ............................................................................................................................................................... 63
        R&D Progress ......................................................................................................................................................................... 63
    PX-866 - Drug Profile .................................................................................................................................................................. 64


Idiopathic Pulmonary Fibrosis – Pipeline Review, H1 2012                                                                                   GMDHC1756IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Idiopathic Pulmonary Fibrosis – Pipeline Review, H1 2012




        Product Description................................................................................................................................................................. 64
        Mechanism of Action ............................................................................................................................................................... 64
        R&D Progress ......................................................................................................................................................................... 64
    Vargatef - Drug Profile ................................................................................................................................................................. 65
        Product Description................................................................................................................................................................. 65
        Mechanism of Action ............................................................................................................................................................... 65
        R&D Progress ......................................................................................................................................................................... 65
    PRM-151 - Drug Profile ............................................................................................................................................................... 67
        Product Description................................................................................................................................................................. 67
        Mechanism of Action ............................................................................................................................................................... 67
        R&D Progress ......................................................................................................................................................................... 67
    STX-100 - Drug Profile ................................................................................................................................................................ 69
        Product Description................................................................................................................................................................. 69
        Mechanism of Action ............................................................................................................................................................... 69
        R&D Progress ......................................................................................................................................................................... 69
    QAX576 - Drug Profile ................................................................................................................................................................. 70
        Product Description................................................................................................................................................................. 70
        Mechanism of Action .......................
								
To top